Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2000 3
2001 2
2002 1
2003 1
2004 1
2005 2
2007 2
2009 2
2010 4
2011 3
2012 5
2013 2
2014 4
2015 3
2016 5
2017 7
2018 5
2019 6
2020 10
2021 10
2022 3
2023 3
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Caimi PF, et al. Among authors: ardeshna km. Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989558 Clinical Trial.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Among authors: ardeshna km. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: ardeshna km. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. Ardeshna KM, et al. Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4. Lancet Oncol. 2014. PMID: 24602760 Clinical Trial.
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.
Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L, Qian W, Rana Z, Martin TL, Townsend W, Young M, Miall F, Cunningham D, Walewski J, Ferhanoglu B, Linton K, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Northend M, et al. Among authors: ardeshna km. Lancet Haematol. 2025 May;12(5):e335-e345. doi: 10.1016/S2352-3026(25)00034-1. Lancet Haematol. 2025. PMID: 40306831 Free article. Clinical Trial.
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
Marzolini MAV, Qian W, Clifton-Hadley L, Patrick P, Warden J, Stevens L, Pocock CFE, Miall F, Cunningham D, Stephens R, Walewski J, Johnston A, Seymour JF, Linch DC, Ardeshna KM. Marzolini MAV, et al. Among authors: ardeshna km. Br J Haematol. 2025 Mar;206(3):876-886. doi: 10.1111/bjh.19918. Epub 2024 Nov 27. Br J Haematol. 2025. PMID: 39604791 Clinical Trial.
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH. Alderuccio JP, et al. Among authors: ardeshna km. Clin Cancer Res. 2024 Jan 5;30(1):139-149. doi: 10.1158/1078-0432.CCR-23-1561. Clin Cancer Res. 2024. PMID: 37855688 Free PMC article.
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Baxter J, Behan S, Bhuller K, Booth S, Chavda ND, Collins GP, Culligan DJ, Cwynarski K, Davies A, Downing A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones SG, Karanth M, Linton KM, Lomas OC, Martinez-Calle N, Mathur A, McKay P, Nagumantry SK, Phillips EH, Phillips N, Rudge JF, Shah NK, Stafford G, Sternberg A, Trickey R, Uttenthal BJ, Wetherall N, Zhang XY, McMillan AK, Coleman N, Stratton MR, Laurenti E, Borchmann P, Borchmann S, Campbell PJ, Rahbari R, Follows GA. Santarsieri A, et al. Among authors: ardeshna km. Lancet Oncol. 2025 Jan;26(1):98-109. doi: 10.1016/S1470-2045(24)00598-9. Epub 2024 Dec 12. Lancet Oncol. 2025. PMID: 39674188 Free article.
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Alderuccio JP, et al. Among authors: ardeshna km. Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782. Blood Adv. 2022. PMID: 35790100 Free PMC article. No abstract available.
76 results